# A Phase 1/2 Study of STP938 (Dencatistat) for Adult Subjects With Relapsed/Refractory B-Cell and T-Cell Lymphomas

Source: https://onco.cc/trials/nct05463263/  
OnCo record `nct05463263` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of STP938 in non-Hodgkin lymphoma, run by Step Pharma, SAS, now recruiting.

## Summary

A Phase 1/2 Study of STP938 (Dencatistat) for Adult Subjects With Relapsed/Refractory B-Cell and T-Cell Lymphomas is a phase 1/2 interventional study registered as NCT05463263 by Step Pharma, SAS, with 180 participants planned, started 2022-08-03 and due to reach its primary completion in 2026-12. Interventions recorded: STP938.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT05463263
- Phase: 1/2
- Setting: An Open-Label, First in Human, Phase 1/2 to Evaluate Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of the CTPS1 Inhibitor STP938 In Adult Subjects With Relapsed/Refractory B-Cell and T-Cell Lymphomas
- Sponsor: Step Pharma, SAS
- Enrolled: 180

## Sources

- ClinicalTrials.gov NCT05463263: https://clinicaltrials.gov/study/NCT05463263

## Connected records

- cancers: [Non-Hodgkin lymphoma (all types)](https://onco.cc/cancers/non-hodgkin-lymphoma/)
- drugs: [STP938](https://onco.cc/drugs/stp938/)

---
JSON: https://onco.cc/api/v1/entities/nct05463263.json